Protocol Ledger

NCT03901729 · Phase II · COMPLETED

A Trial to Study BAY1753011 in Patients With Congestive Heart Failure

Interventional Phase II clinical trial protocol NCT03901729 sponsored by Bayer in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-05-29 Enrollment: 482 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03901729
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)482 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03901729
Protocol FieldVerified Registry Value
NCT IdentifierNCT03901729
Consolidated Lead SponsorBayer
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment482 participants (ACTUAL)
Registered Start Date2019-05-29
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI